AbbVie submits sNDA to FDA for major depressive disorder therapy

AbbVie submits sNDA to FDA for major depressive disorder therapy

Submitted by admin on February 23, 2022 - 10:18am
Source: 
Pharmaceutical Business Review
News Tags: 
AbbVie
FDA
cariprazine
major depressive disorder
Headline: 
AbbVie submits sNDA to FDA for major depressive disorder therapy
snippet: 

Cariprazine is intended for the adjunctive treatment of MDD patients who are receiving ongoing antidepressant therapy. The company’s sNDA submission is based on data obtained from clinical trials

Do Not Allow Advertisers to Use My Personal information